The 2018 Hewitt Healthcare Lecture focused on value-based payment arrangements and other creative reimbursement solutions for innovative therapies. New England is home to the world’s greatest cluster of life sciences companies. Many are developing specialty or higher cost therapies that treat rare diseases with smaller patient populations. Effective reimbursement strategies will allow innovation to continue and expand patient access to new life-changing treatments.
Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Margolis Center for Health Policy at Duke University. He is a physician-economist who focuses on quality and value in health care including payment reform, real-world evidence, and more effective drug and device innovation. Dr. McClellan is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. He was previously Senior Fellow at the Brookings Institution and a faculty member at Stanford University.